No connection

Search Results

GDRX vs IART

GDRX
GoodRx Holdings, Inc.
BEARISH
Price
$2.16
Market Cap
$740.0M
Sector
Healthcare
AI Confidence
85%
IART
Integra LifeSciences Holdings Corporation
NEUTRAL
Price
$9.90
Market Cap
$771.6M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
GDRX
24.0
IART
--
Forward P/E
GDRX
5.88
IART
3.86
P/B Ratio
GDRX
1.2
IART
0.74
P/S Ratio
GDRX
0.93
IART
0.47
EV/EBITDA
GDRX
8.35
IART
8.54

Profitability

Gross Margin
GDRX
92.77%
IART
56.23%
Operating Margin
GDRX
18.98%
IART
12.44%
Profit Margin
GDRX
3.82%
IART
-31.58%
ROE
GDRX
4.54%
IART
-39.9%
ROA
GDRX
4.75%
IART
2.39%

Growth

Revenue Growth
GDRX
-1.9%
IART
-1.7%
Earnings Growth
GDRX
-9.7%
IART
--

Financial Health

Debt/Equity
GDRX
0.88
IART
1.95
Current Ratio
GDRX
2.61
IART
2.54
Quick Ratio
GDRX
2.1
IART
1.19

Dividends

Dividend Yield
GDRX
--
IART
--
Payout Ratio
GDRX
0.0%
IART
0.0%

AI Verdict

GDRX BEARISH

GDRX exhibits a fragile financial profile with a Piotroski F-Score of 4/9, indicating only marginal stability. The stock is currently trading at $2.16, which is a premium to its Graham Number ($1.91) and significantly above its growth-based intrinsic value ($0.63). Fundamental decay is evident through negative YoY revenue (-1.90%) and earnings growth (-9.70%), compounded by a streak of four consecutive earnings misses. With a 5-year price collapse of 94.7% and bearish insider sentiment, the data suggests a company in a structural decline.

Strengths
Exceptionally high gross margins (92.77%)
Strong short-term liquidity with a current ratio of 2.61
Low Price-to-Sales ratio (0.93) suggesting low valuation relative to revenue
Risks
Negative revenue and earnings growth trends
Consistent failure to meet analyst earnings estimates (0/4 last 4 quarters)
Severe long-term price erosion (-94.7% over 5 years)
IART NEUTRAL

IART presents as a classic deep-value turnaround candidate with a stable Piotroski F-Score of 6/9, indicating reasonable operational health despite severe price depreciation. The company is trading at a significant discount to book value (P/B 0.74) and possesses a very low forward P/E of 3.86, suggesting the market has over-priced the risk. However, negative net profit margins (-31.58%) and stagnant revenue growth (-1.70%) offset the valuation appeal. The stark contrast between the current price ($9.90) and the analyst target ($15.57) indicates potential upside, but the bearish technical trend remains a primary headwind.

Strengths
Deep value valuation with P/B of 0.74 and P/S of 0.47
Strong short-term liquidity with a Current Ratio of 2.54
Stable financial health baseline (Piotroski F-Score 6/9)
Risks
Severe long-term price erosion (-85.7% over 5 years)
Negative net profit margins (-31.58%) impacting bottom-line stability
Stagnant to declining revenue growth (YoY -1.70%)

Compare Another Pair

GDRX vs IART: Head-to-Head Comparison

This page compares GoodRx Holdings, Inc. (GDRX) and Integra LifeSciences Holdings Corporation (IART) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile